LYNPARZA® Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer Pharmaceutical Investing
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results Pharmaceutical Investing
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights Pharmaceutical Investing
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis Pharmaceutical Investing
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® Plus LENVIMA® Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Pharmaceutical Investing
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference Pharmaceutical Investing
